BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Dihydroergotamine

A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.

299+ PubMed studies analyzed · 37 RCTs · Evidence Score: 48.9

Research Domains

Dihydroergotamine has been studied across 15 research domains including 💊 Pain, ❤️ Cardiovascular, 🌤️ Mood & Depression, 🧠 Focus & Attention, 🫁 Respiratory. The primary research focus is 💊 Pain with 25% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dihydroergotamine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Yohimbine
30 shared targets
Pergolide
28 shared targets
Lisuride
27 shared targets
Ergotamine
25 shared targets
Oxymetazoline
22 shared targets
Bromocriptine
31 shared targets
Quetiapine
28 shared targets
Mianserin
29 shared targets
Buspirone
24 shared targets
Dexmedetomidine
15 shared targets
Loading evidence profile...

This evidence profile for Dihydroergotamine is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.